Articles & Video
Biopharma Partnering and Financing Trends, H1 2020
With the help of Biomedtracker, analysts at Pharma Intelligence have taken a deep dive into the worldwide biopharma industry partnership and financial dealmaking during the first halves of 2019 and 2020. What they found is astounding and inside the new white paper.
Biotech Startups: How to Succeed in a COVID-19 World
Taking a biotech company from concept, through clinical trials, and ultimately to market requires a perfect storm of good science, a sound investment, and the right management. This ebook is here to guide startups through this journey.
Interview: Promoting prosperity in the life science sectors of China and the UK
In this exclusive interview, Her Majesty’s Trade Commissioner for China at the Department for International Trade, John Edwards, discusses how China’s healthcare and life sciences markets are growing rapidly and are driven by increased demand and changes to regulations, plus much more.
Interview: Importance of diversity and partnering in global life sciences
ATLATL Innovation Cluster (IC) in the heart of Zhangjiang Pharma Valley. Its Founder and CEO, Dr. P.C. Zhu, designed it to be a launchpad for high-potential life sciences in China. In this interview with EBD Group he discusses the opportunities ATLATL provides and the importance of partnering in the life science industry.
Video Interview - Johnson & Johnson’s approach to external innovation
William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence, ahead of ChinaBio® Partnering Forum Digital.
Interview – J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.
REPORT: State of China Life Science - 2020 H1
Download this new exclusive ChinaBio® report with in-depth analysis of investment and partnering activity in China for 2020 H1 to discover the factors driving China life science investment. Learn how VC, IPO, and Partnering have rebounded despite COVID-19, but how M&A continues to slump.
Top Biotech Deals in China
Discover the deals transforming China biotech! More than $12 billion in biopharma financing, alliances, IPOs, and new funds have been generated so far this year in China. Learn the details of these deals when you read this new free infographic.
China's Challenges and Opportunities in the Wake of COVID-19
Discover how pharma companies in China are collaborating like never before to keep the supply chain from breaking, as well as asking the government to help address a flurry of issues laid bare by the public health crisis.
Interview- Roche’s approach to drug discovery, innovation and meeting patients' needs
James Sabry, Global Head of Roche Pharma Partnering, discusses Roche’s approach to discovering scientific breakthroughs, accelerating innovative research, collaborating with stakeholders, and meeting unmet medical needs in China and around the world.